• Does DAA Therapy for HCV Infection Increase Survival in Patients Who Have Responded to Treatment for Hepatocellular Carcinoma?

Does DAA Therapy for HCV Infection Increase Survival in Patients Who Have Responded to Treatment for Hepatocellular Carcinoma?

2562 11 months ago 0

In patients who have received successful treatment for HCV-related hepatocellular carcinoma (HCC), eradication of the HCV infection with direct-acting antiviral (DAA) significantly reduces risk of death, researchers report in the November issue of Gastroenterology. Chronic hepatitis C virus (HCV) infection is the most common cause of HCC in North America and Europe. DAA

Read more
  • Does Placement on a Distant Liver Waitlist Increase Chances of Transplantation?

Does Placement on a Distant Liver Waitlist Increase Chances of Transplantation?

2510 11 months ago 0

Placement on a liver transplant waitlist outside of a patient’s home region can reduce mortality and increase odds of receiving a liver, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Strategies are needed to overcome geographic differences in access to livers for transplantation, which are more likely

Read more
  • How Does Estrogen Receptor Signaling Promote Growth of Liver Tumors?

How Does Estrogen Receptor Signaling Promote Growth of Liver Tumors?

2679 1 year ago 0

The G-protein–coupled estrogen receptor (GPER1) is a hepatic sensor of estrogen that regulates liver growth during development, regeneration, and tumorigenesis, researchers show in a study of zebrafish and human liver published in the May issue of Gastroenterology. Inhibitors of GPER1 might be developed for liver cancer prevention or treatment. Liver cancer

Read more
  • Should We Screen for HCC?

Should We Screen for HCC?

3638 2 years ago 0

Screening patients with cirrhosis for hepatocellular carcinoma (HCC) by abdominal ultrasonography (USS) and/or measurement of serum level of alpha-fetoprotein (AFP) is not associated with reduced mortality from this cancer, reseachers report from a matched case–control study in the October issue of Gastroenterology. Patients with cirrhosis have a high risk (1%–8%

Read more
  • A Genetic Cause for Multiple Adenomas and Diabetes in a Young Patient

A Genetic Cause for Multiple Adenomas and Diabetes in a Young Patient

2953 2 years ago 0

Researchers report a case of a patient with multiple adenomas and a family history of young-onset diabetes and hepatocellular carcinoma. They found these to be caused by a mutation in the HNF1 homeobox A gene (HNF1A), which caused maturity onset diabetes of the young type 3 (MODY3). Tom J. Harryvan et al evaluated a

Read more
  • Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

4482 3 years ago 0

A sustained virologic response (SVR) to all-oral therapy in patients with hepatitis C virus (HCV)-associated cirrhosis significantly reduces the hepatic venous pressure gradient (HVPG), researchers report in the November issue of Gastroenterology. Nevertheless, almost 80% of patients maintain significant portal hypertension and have a continued risk of decompensation. In patients with compensated

Read more
  • What is the Best Management Strategy for Patients With NAFLD?

What is the Best Management Strategy for Patients With NAFLD?

9472 3 years ago 0

Management of patients with non-alcoholic fatty liver disease (NAFLD) requires combined efforts of general practitioners, hepatologists, and other experts, Herbert Tilg explains in a Mentoring, Education, and Training Corner article in the August issue of Gastroenterology. NAFLD has become the most common liver disease worldwide. It ranges from simple steatosis in the absence

Read more
  • Bioinformatic Search Identifies Tapeworm Drug for Treatment of Hepatocellular Carcinoma

Bioinformatic Search Identifies Tapeworm Drug for Treatment of Hepatocellular Carcinoma

6334 3 years ago 0

In a bioinformatic search for agents that alter the hepatocellular carcinoma (HCC)-specific gene expression pattern, researchers identified the anthelmintic drug niclosamide as a potential anti-tumor agent, described in the June issue of Gastroenterology. Niclosamide and its ethanolamine salt (NEN), with greater bioavailability, slowed growth of genetically induced liver tumors and

Read more
  • What are the Different Types of Liver Cancer, and How do They Develop?

What are the Different Types of Liver Cancer, and How do They Develop?

6392 4 years ago 0

A review article in the March issue of Gastroenterology discusses different hypotheses about the cells responsible for liver tumorigenesis. The article also reviews the different classes of liver tumors, based on the molecular features, and how these affect patient prognosis. Daniela Sia et al describe the distinct molecular and clinical features of hepatocellular

Read more
  • How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

5809 4 years ago 0

Researchers have developed a patient-derived cell line-based model to study how intratumor heterogeneity affects sensitivity of hepatocellular carcinoma (HCC) to different therapeutic agents, reported in the January issue of Gastroenterology. HCCs have a large amount of genetic heterogeneity within each tumor, making them difficult to treat. Multiple regions of tumors

Read more